Aktuelle Studien

Astra Zeneca – EUDRACT Nr. 2024-514506-32
Rekrutierungsphase laufend
A Phase 3, Randomised, Double-blind, Placebo-controlled, Event-driven Study to Evaluate
the Effect of Baxdrostat in Combination with Dapagliflozin Compared with Dapagliflozin
Alone on the Risk of Incident  Heart Failure and Cardiovascular Death in Participants with
Increased Risk of Developing Heart Failure

Novartis – EUDRACT Nr. 2024-516356-18
Rekrutierungsphase laufend
A randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy, safety,
and tolerability of pelacarsen (TQJ230) with background inclisiran in participants with atherosclerotic
cardiovascular disease, and elevated LDL-C and Lp(a)

FIDAM – Medizin-produkt Studie
Rekrutierungsphase laufend
Continuous Glucose Monitoring in People with Type 2 Diabetes on Basal Insulin – The Basal.DE Study

Novartis – EUDRACT Nr. 2024-519870-38-00
Rekrutierungsphase laufend
A single arm, multicenter, open-label extension (OLE) trial to evaluate long-term safety and
tolerability of pelacarsen (TQJ230) in participants who completed the parent Lp(a)HORIZON trial

Astra Zeneca – EUDRACT Nr. 2025-520519-14
Rekrutierungsphase laufend
A Phase 3, Randomised, Double blind, Placebo controlled, Parallel group Study to Assess the
Effect of AZD0780 on Major Adverse Cardiovascular Events in Patients with Established
Atherosclerotic Cardiovascular Disease (ASCVD) or at High Risk for a First ASCVD Event

Roche – EUDRACT Nr. 2025-523106-32-00
Rekrutierungsphase laufend
A Phase 3, randomized, double-blind, Placebo controlled, parallel group study to evaluate
the efficacy and safety of once-weekly RO7795068 Administered to Participants with obesity
or overweight and Type 2 Diabetes

Novo Nordisk – EUDRACT Nr. 2026-525209-11
Rekrutierungsphase laufend
Efficacy and safety of zenagamtide s.c. once weekly compared to insulin glargine s.c. once
daily in participants with type 2 diabetes and increased cardiovascular risk inadequately
controlled on 1–3 oral glucose-lowering medications (AMBITION 7)

Alnylam – EUDRACT Nr. 2025-522960-34
Rekrutierungsphase laufend
ZENITH: A Phase 3 Global, Randomized, Double-blind, Placebocontrolled Study to Evaluate
the Efficacy and Safety of Zilebesiran in Addition to Standard of Care in Reducing Major
Adverse Cardiovascular Events in Adult Patients with Hypertension Not Adequately Controlled
and With Either Established Cardiovascular Disease or High Risk for Cardiovascular Disease

ACCLAIM-Lp(a) – Lilly – EUDRACT Nr. 2023-509190-23-00
Rekrutierungsphase laufend
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Effect of
Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults with Elevated
Lipoprotein(a) who have Established Atherosclerotic Cardiovascular Disease or Are at Risk for a
First Cardiovascular Event

SURPASS-EARLY – Lilly – EUDRACT Nr. 2022-501073-40-00
Rekrutierungsphase laufend
A Randomized, Open-Label, Parallel-Group, Two-Arm, Phase 4 Study to
Evaluate the Long-Term Efficacy and Safety of Tirzepatide Compared with Intensified
Conventional Care in Adults When Initiating Treatment Early in the Course of Type 2 Diabetes